AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
France-based pharmaceutical company Aventis SA has ended clinical development of its M100,240 drug for the treatment of high blood pressure.
The decision to terminate the cardiovascular drug's development was based on a recently completed Phase II clinical trial in hypertension, in which the drug did not meet the company's criteria for further development. Aventis noted that it is still evaluating M100,240's potential for treating other conditions.
Aventis also has a back-up candidate to M100,240, AVE-7688, in Phase I trials for the treatment of hypertension and congestive heart failure. The …